Angiopoietin-1 and -2 expression in recurrent squamous cell carcinoma of the oral cavity

Journal of Surgical Oncology

Volumn 97, Issue 3, 2008, Pages 273-277

  Chien, Chih Yen ^a,b   Su, Chih Ying ^a,b   Chuang, Hui Ching ^a,b   Fang, Fu Min ^a,b   Huang, Hsuan Ying ^a,b   Chen, Ching Mei ^a   Chen, Chang Han ^a,b   Huang, Chao Cheng ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; Angiopoietin 1; Angiopoietin 2; Prognosis; Recurrent oral cancer

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION;

EID: 39749103686     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20930     Document Type: Article

References (27)

1. 1 Schwartz GJ, Mehta RH, Wenig BL, et al.: Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. Head Neck 2000 ; 22: 34–41.
2. 2 Yuen AP, Wei WI, Wong SH, et al.: Local recurrence of carcinoma of the tongue after glossectomy: Patient prognosis. Ear Nose Throat J 1998 ; 77: 181–184.
3. 3 Shah JP, Cendon RA, Farr HW, et al.: Carcinoma of the oral cavity. Factors affecting treatment failure at the primary site and neck. Am J Surg 1976 ; 132: 504–507.
4. 4 Nathanson A, Agren K, Biorklund A, et al.: Evaluation of some prognostic factors in small squamous cell carcinoma of the mobile tongue: A multicenter study in Sweden. Head Neck 1989 ; 11: 387–392.
5. 5 Pearlman NW: Treatment outcome in recurrent head and neck cancer. Arch Surg 1979 ; 114: 39–42.
6. 6 Jones KR, Lodge‐Rigal RD, Reddick RL, et al.: Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg 1992 ; 118: 483–485.
7. 7 Boysen M, Lovdal O, Tausjo J, et al.: The value of follow‐up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer 1992 ; 28: 426–430.
8. 8 Meyza JW, Towpik E: Surgical and cryosurgical salvage of oral and oropharyngeal cancer recurring after radical radiotherapy. Eur J Surg Oncol 1991 ; 17: 567–570.
9. 9 Wong LY, Wei WI, Lam LK, et al.: Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003 ; 25: 953–959.
10. 10 Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002 ; 29: 15–18.
11. 11 Chien CY, Su CY, Hwang CF, et al.: High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis. J Surg Oncol 2006 ; 94: 413–417.
12. 12 Weidner N: Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 1995 ; 147: 9–19.
13. 13 Polverini PJ, Leibovich SJ: Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor associated macrophages. Lab Invest 1984 ; 51: 635–642.
14. 14 Davis S, Aldrich TH, Jones PF, et al.: Isolation of angiopoietin‐1, a ligand for the TIE2 receptor, by secretion‐trap expression cloning. Cell 1996 ; 87: 1161–1169.
15. 15 Maisonpierre PC, Suri C, Jones PF, et al.: Angiopoietin‐2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997 ; 277: 55–60.
16. 16 Holash J, Maisonpierre PC, Compton D, et al.: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science. 1999 ; 284: 1994–1998.
17. 17 Wang J, Wu K, Zhang D, et al.: Expressions and clinical significances of angiopoietin‐1, ‐2 and Tie2 in human gastric cancer. Biochem Biophys Res Commun 2005 ; 337: 386–393.
18. 18 Ryan WR, Fee WE, Jr., Le QT, et al.: Positron‐emission tomography for surveillance of head and neck cancer. Laryngoscope 2005 ; 115: 645–650.
19. 19 Zimmer LA, Branstetter BF, Nayak JV, et al.: Current use of 18F‐fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 2005 ; 115: 2029–2034.
20. 20 Suri C, Jones PF, Patan S, et al.: Requisite role of angiopoietin‐1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996 ; 87: 1171–1180.
21. 21 Suri C, McClain J, Thurston G, et al.: Increased vascularization in mice overexpressing angiopoietin‐1. Science 1998 ; 282: 468–471.
22. 22 Thurston G, Suri C, Smith K, et al.: Leakage‐resistant blood vessels in mice transgenically overexpressing angiopoietin‐1. Science 1999 ; 286: 2511–2514.
23. 23 Zheng MH, Veelken F, Labbe D, et al.: Expression of angiopoietin‐1 and 2 in squamous cell carcinoma of the head and neck areas and normal mucosa. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2005 ; 40: 371–375.
24. 24 Chung YC, Hou YC, Chang CN, et al.: Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 2006 ; 94: 631–638.
25. 25 Stoeltzing O, Ahmad SA, Liu W, et al.: Angiopoietin‐1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003 ; 63: 3370–3377.
26. 26 Hawighorst T, Skobe M, Streit M, et al.: Activation of the tie2 receptor by angiopoietin‐1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002 ; 160: 1381–1392.
27. 27 Sugimachi K, Tanaka S, Taguchi K, et al.: Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 2003 ; 56: 854–860.